How did you figure that out? What criteria? Agreed, it is difficult to evaluate at times given pipelines in progress and acquisitions they do from time to time. Fiscal cliff distorts so many things right now.
Even more difficult when it comes to biotech. I use various methodologies such as rigorous DCF valuation, relative valuation and technical and momentum assessment when evaluating stocks. It also has a lot to do with the overall macro outlook of the markets in general. Taxes rising and growth stagnating with many companies forecasting negatively. With a price to sales ratio of near 5... AGN is worth 28.3B and 5.7B in sales. If AGN price to sales slides closer to 4 it is still worth 20B and under $75.00. I don't have anything against the company it just not a good time to be investing.